U.S. health regulators have approved the first cancer fighting therapy that works by genetically altering a patient’s cells.
The drug from Swiss pharmaceutical giant Novartis offers children with a hard-to-treat form of leukemia a chance at complete remission.
But at nearly half a million dollars, it’s raising concerns about an unsustainable rise in cancer treatment costs.
CGTN’s Daniel Ryntjes reports.
Wendell Potter discusses the high price for life-save drugs
CGTN’s Rachelle Akuffo spoke with author and former insurance industry executive Wendell Potter about the high price of life saving drugs.